Opponents on the football field, a group of eleven schools from the Big Ten athletic conference came together this summer to launch an ambitious new effort against a common foe: cancer.
“By uniting to transform cancer research through collaborative oncology trials, we will be able to leverage the scientific and clinical expertise of the Big Ten universities,” said Steven T. Rosen, MD, Genevieve E. Teuton Professor of Medicine and director of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University. “The consortium will benefit patients because researchers will work together to turn ideas into potential new treatments. …”
The Big Ten Cancer Research Consortium is meant to transform cancer research through collaborative trials that leverage the scientific and clinical expertise of each university, utilizing geographical locations and existing relationships. Newly developed clinical trials will be linked to molecular diagnostics, enabling researchers to understand what drives the cancers to grow and what might be done to stop their growth.
The consortium is meant to create a unique team-research culture in which senior faculty work with and mentor junior faculty and fellows, giving them the opportunity to write, conduct, and complete trials, which would not normally be done at a single institution or on a national level.
The 11 participating schools are: Indiana University, Northwestern University, Penn State University, Purdue University, Rutgers University, the University of Illinois, University of Iowa, University of Michigan, University of Minnesota, University of Nebraska, and University of Wisconsin.